Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: A nationwide cohort study

Journal of the American College of Cardiology

Volumn 57, Issue 4, 2011, Pages 409-417

  Olesen, Jonas B ^a   Gislason, Gunnar H ^a   Charlot, Mette G ^a   Fosbøl, Emil L ^a   Andersson, Charlotte ^a   Weeke, Peter ^a   Ahlehoff, Ole ^a   Selmer, Christian ^a   Torp Pedersen, Christian ^a   Hansen, Peter R ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anatomical Therapeutic Chemical; ATC; calcium channel blocker; CCB; CYP; cytochrome P 450; ICD; International Classification of Diseases; MI; myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIDIABETIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; LOOP DIURETIC AGENT; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; SPIRONOLACTONE; VERAPAMIL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PEPTIC ULCER; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SHOCK; SOCIAL STATUS; STROKE;

AGED; CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78751664025     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.08.640     Document Type: Article

References (40)

1. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/nonST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) J Am Coll Cardiol 50 2007 e1 e157
2. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
3. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900
4. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
5. J.M. Pereillo, M. Maftouh, and A. Andrieu Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
6. P. Savi, J.M. Pereillo, and M.F. Uzabiaga Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
7. M. Katoh, M. Nakajima, N. Shimada, H. Yamazaki, and T. Yokoi Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions Eur J Clin Pharmacol 55 2000 843 852
8. S. Nishio, H. Watanabe, K. Kosuge, S. Uchida, H. Hayashi, and K. Ohashi Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension Hypertens Res 28 2005 223 227
9. H. Watanabe, K. Kosuge, and S. Nishio Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension Life Sci 76 2004 281 292
10. A.M. Harmsze, K. Robijns, and J.W. van Werkum The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response Thromb Haemost 103 2010 920 925
11. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
12. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
13. T.F. Andersen, M. Madsen, J. Jorgensen, L. Mellemkjoer, and J.H. Olsen The Danish National Hospital Register A valuable source of data for modern health sciences Dan Med Bull 46 1999 263 268
14. D. Gaist, H.T. Sorensen, and J. Hallas The Danish prescription registries Dan Med Bull 44 1997 445 448
15. R. Sorensen, G.H. Gislason, and E.L. Fosbol Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study Br J Clin Pharmacol 66 2008 875 884
16. M. Madsen, M. Davidsen, S. Rasmussen, S.Z. Abildstrom, and M. Osler The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry J Clin Epidemiol 56 2003 124 130
17. L.H. Krarup, G. Boysen, H. Janjua, E. Prescott, and T. Truelsen Validity of stroke diagnoses in a National Register of Patients Neuroepidemiology 28 2007 150 154
18. J.V. Tu, P.C. Austin, R. Walld, L. Roos, J. Agras, and K.M. McDonald Development and validation of the Ontario acute myocardial infarction mortality prediction rules J Am Coll Cardiol 37 2001 992 997
19. S. Rasmussen, A.D. Zwisler, S.Z. Abildstrom, J.K. Madsen, and M. Madsen Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals Med Care 43 2005 970 978
20. G.H. Gislason, S. Jacobsen, and J.N. Rasmussen Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction Circulation 113 2006 2906 2913
21. Greedy Matching Macro http://www2.sas.com/proceedings/sugi26/p214-26.pdf Accessed December 3, 2010.
22. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
23. W. Hochholzer, D. Trenk, and M.F. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
24. U. Klotz Antiarrhythmics: elimination and dosage considerations in hepatic impairment Clin Pharmacokinet 46 2007 985 996
25. P. Gladding, M. Webster, and I. Zeng The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial J Am Coll Cardiol Intv 1 2008 612 619
26. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
27. W.C. Lau, L.A. Waskell, and P.B. Watkins Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37
28. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
29. A. Blagojevic, J.A. Delaney, L.E. Levesque, N. Dendukuri, J.F. Boivin, and J.M. Brophy Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study Pharmacoepidemiol Drug Saf 18 2009 362 369
30. J. Saw, D.M. Brennan, and S.R. Steinhubl Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial J Am Coll Cardiol 50 2007 291 295
31. J. Saw, S.R. Steinhubl, and P.B. Berger Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
32. M.J. Lim, F.A. Spencer, and J.M. Gore Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry Eur Heart J 26 2005 1063 1069
33. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
34. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
35. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
36. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, J.W. Jukema, and M.V. Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am Heart J 154 2007 221 231
37. C. Combescure, P. Fontana, and N. Mallouk Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 8 2010 923 933
38. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
39. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic Determinants of Response to Clopidogrel and Cardiovascular Events N Engl J Med 360 2009 363 375
40. C. Varenhorst, S. James, and D. Erlinge Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752